SG11201907571WA - Therapeutic compositions and related methods for photoimmunotherapy - Google Patents

Therapeutic compositions and related methods for photoimmunotherapy

Info

Publication number
SG11201907571WA
SG11201907571WA SG11201907571WA SG11201907571WA SG11201907571WA SG 11201907571W A SG11201907571W A SG 11201907571WA SG 11201907571W A SG11201907571W A SG 11201907571WA SG 11201907571W A SG11201907571W A SG 11201907571WA SG 11201907571W A SG11201907571W A SG 11201907571WA
Authority
SG
Singapore
Prior art keywords
conjugates
international
dual
california
photoimmunotherapy
Prior art date
Application number
SG11201907571WA
Inventor
Miguel Garcia-Guzman
Lewis R Makings
Eileen Sun Chin
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of SG11201907571WA publication Critical patent/SG11201907571WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

International Patent Classification: (72) Inventors: GARCIA-GUZMAN, Miguel; 11080 Roselle A61K 41/00 (2006.01) A61K 47/62 (2017.01) Street, San Diego, California 92121 (US). MAKINGS, A61K 47/42 (2017.01) A61K 47/68 (2017.01) Lewis R.; 11080 Roselle Street, San Diego, California A61K 47/50 (2017.01) A61P 35/00 (2006.01) 92121 (US). CHIN, Eileen Sun; 11080 Roselle Street, San (21) International Application Number: Diego, California 92121 (US). PCT/US2018/019294 (22) International Filing Date: 22 February 2018 (22.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/462,898 23 February 2017 (23.02.2017) US (71) Applicant: ASPYRIAN THERAPEUTICS, INC. [US/US]; 11080 Roselle Street, San Diego, California 92121 (US). (74) Agent: AHN, Sejin; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIPO I PCT (54) Title: THERAPEUTIC COMPOSITIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY FIG. 1A 0111111010 0111 °nolo monim H OH oimIE (10) International Publication Number WO 2018/156815 Al 25 O I • 20 72 • , -- c 15 0, ° co • -q. 0 10 • -a • ez • 5 u_ 0 ENo light 0 Light 00 00 O C A431+CetuximabIR700 FaDu+Cetuximab I R700 Treatment (57) : Provided are conjugates, e.g., dual conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye in the dual conjugate. In some embodiments, the dual conjugate contains a targeting molecule and a therapeutic agent. In some embodiments, the phthalocyanine-dye in the conjugate, e.g., dual con- jugate, can be activated by irradiation with near-infrared light. Also provided are therapeutic methods using the conjugates, e.g., dual conjugates, and compositions for treatment of a lesion associated with diseases and conditions, including tumors or cancers. Features of the conjugates, e.g., dual conjugates, compositions, combinations and methods, including the dose of the conjugate, provide various advantages, such as efficient delivery and targeting of the therapeutic agent to the site of the lesion. [Continued on next page] WO 2018/156815 Al MIDEDIMOMOIDEIREEMOMOMHOHOMMIS SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201907571WA 2017-02-23 2018-02-22 Therapeutic compositions and related methods for photoimmunotherapy SG11201907571WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462898P 2017-02-23 2017-02-23
PCT/US2018/019294 WO2018156815A1 (en) 2017-02-23 2018-02-22 Therapeutic compositions and related methods for photoimmunotherapy

Publications (1)

Publication Number Publication Date
SG11201907571WA true SG11201907571WA (en) 2019-09-27

Family

ID=63253005

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907571WA SG11201907571WA (en) 2017-02-23 2018-02-22 Therapeutic compositions and related methods for photoimmunotherapy

Country Status (8)

Country Link
US (1) US20190365897A1 (en)
EP (1) EP3585433A4 (en)
JP (1) JP2020508323A (en)
CN (1) CN110545846A (en)
AU (1) AU2018225177A1 (en)
CA (1) CA3053573A1 (en)
SG (1) SG11201907571WA (en)
WO (1) WO2018156815A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
CN111388672A (en) 2014-08-08 2020-07-10 美国政府(由卫生和人类服务部的部长所代表) Photocontrolled removal of targets in vivo and in vitro
CA2994822C (en) 2015-08-07 2023-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
DK3337568T3 (en) 2015-08-18 2021-09-27 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
CN108136039A (en) 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 For the composition of photoimmunotherapy, combination and correlation technique
US10682602B2 (en) * 2017-01-19 2020-06-16 National University Of Singapore Nanofibrous filter
TW201837051A (en) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2019350466A1 (en) * 2018-09-28 2021-04-29 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
EP3948274A1 (en) * 2019-03-29 2022-02-09 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020247598A1 (en) * 2019-06-05 2020-12-10 Emory University Photolysis to unlock caged protein therapeutics
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2023505222A (en) * 2019-12-06 2023-02-08 ラクテン・メディカル，インコーポレイテッド Methods for immune enhancement and tumor treatment
EP4073102A2 (en) 2019-12-12 2022-10-19 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
CN111057063B (en) * 2019-12-19 2022-06-14 福州大学 Phthalocyanine derivative for targeted photodynamic therapy of acute lymphocytic leukemia and preparation method thereof
CN111423497B (en) * 2020-03-16 2021-12-24 山东大学 Antagonistic peptide, copolymer and nano assembly thereof, and preparation method and application thereof
US20240101685A1 (en) * 2021-01-29 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
WO2009038776A1 (en) * 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN107252485A (en) * 2013-04-03 2017-10-17 Ibc药品公司 For inducing the combination treatment to the immune response of disease
US10011587B2 (en) * 2014-05-15 2018-07-03 The Methodist Hospital System Multivalent ligands targeting VEGFR
CN111388672A (en) * 2014-08-08 2020-07-10 美国政府(由卫生和人类服务部的部长所代表) Photocontrolled removal of targets in vivo and in vitro
DK3337568T3 (en) * 2015-08-18 2021-09-27 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
CN108136039A (en) * 2015-08-18 2018-06-08 阿斯皮利安治疗学股份有限公司 For the composition of photoimmunotherapy, combination and correlation technique

Also Published As

Publication number Publication date
EP3585433A4 (en) 2020-12-30
JP2020508323A (en) 2020-03-19
CN110545846A (en) 2019-12-06
EP3585433A1 (en) 2020-01-01
US20190365897A1 (en) 2019-12-05
WO2018156815A1 (en) 2018-08-30
AU2018225177A1 (en) 2019-09-05
CA3053573A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
SG11201907571WA (en) Therapeutic compositions and related methods for photoimmunotherapy
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201908131RA (en) Benzazepine compounds, conjugates, and uses thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201811432WA (en) Rna for cancer therapy
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201809982RA (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201811559WA (en) Cancer treatment combinations
SG11201908512YA (en) Somatostatin modulators and uses thereof